TIROFIBAN - INJECTION
Common Brand Name(s): Aggrastat
Phonetic Pronunciation: (teer-OH-fih-ban)
Information last revised November 2010
What does TIROFIBAN - INJECTION look like?
Aggrastat 5 mg/100 mL (50 mcg/mL) IV
Aggrastat 12.5 mg/250 mL (50 mcg/mL) IV
Tirofiban is a type of "blood thinner" used to prevent blood clots that can cause a heart attack or other serious blood flow problems. It is used before certain procedures to open up the blood vessels in the heart (e.g., balloon angioplasty, coronary stent placement, percutaneous coronary intervention-PCI, coronary artery bypass graft-CABG). It is also used with other medications (e.g., nitrates, beta blockers) to stop or prevent a heart attack in people with continuing chest pain when the above procedures cannot be done. It is usually used with heparin and aspirin. Tirofiban works by preventing platelets in the blood from sticking to each other. When platelets stick to each other, they may form blood clots that may cause a heart attack or cause the opened blood vessel in the heart to close back up.
This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
The information contained in the First DataBank databases is intended to supplement the knowledge of physicians, pharmacists, and other healthcare professionals regarding drug therapy problems and patient counselling information. This information is advisory only and is not intended to replace sound clinical judgment in the delivery of healthcare services. First DataBank disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, and suitability of this information for any purpose.
Copyright 2010 First DataBank, Inc.